Cell MedX Corp.
CMXC · OTC
5/31/2025 | 5/31/2024 | 5/31/2023 | 5/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.23 | 1.92 | 4.76 |
| FCF Yield | -1.74% | -7.84% | -0.99% | -0.48% |
| EV / EBITDA | 0.00 | 0.00 | -63.16 | -141.36 |
| Quality | ||||
| ROIC | 0.00% | 61.43% | 32.45% | 50.02% |
| Gross Margin | 0.00% | 0.00% | 17.49% | 66.50% |
| Cash Conversion Ratio | 0.25 | 1.02 | 0.55 | 0.65 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -25.80% | -60.15% |
| Free Cash Flow Growth | 2.95% | 46.40% | 39.59% | 19.82% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | 0.00 | -2.02 | -0.88 |
| Interest Coverage | 0.00 | -5.08 | -9.45 | -26.15 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | -0.23 |
| Cash Conversion Cycle | 0.00 | 0.00 | -64,960.55 | -80,521.67 |